Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

PURPOSE: Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Stroes, Charlotte I., Schokker, Sandor, Creemers, Aafke, Molenaar, Remco J., Hulshof, Maarten C.C.M., van der Woude, Stephanie O., Bennink, Roel J., Mathôt, Ron A.A., Krishnadath, Kausilia K., Punt, Cornelis J.A., Verhoeven, Rob H.A., van Oijen, Martijn G.H., Creemers, Geert-Jan, Nieuwenhuijzen, Grard A.P., van der Sangen, Maurice J.C., Beerepoot, Laurens V., Heisterkamp, Joos, Los, Maartje, Slingerland, Marije, Cats, Annemieke, Hospers, Geke A.P., Bijlsma, Maarten F., van Berge Henegouwen, Mark I., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2020
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007286/
https://ncbi.nlm.nih.gov/pubmed/31809243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01814
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars